We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Basilea Pharmaceutica AG (BSLN) CHF1 (Regd)

Sell:37.40 CHF Buy:38.00 CHF Change: 0.1 CHF (0.26%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:37.40 CHF
Buy:38.00 CHF
Change: 0.1 CHF (0.26%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
Sell:37.40 CHF
Buy:38.00 CHF
Change: 0.1 CHF (0.26%)
Market closed |  Prices as at close on 28 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

Contact details

Address:
Hegenheimermattweg 167b
ALLSCHWIL
4123
Switzerland
Telephone:
+41 (61) 6061111
Website:
https://www.basilea.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BSLN
ISIN:
CH0011432447
Market cap:
493.27 million CHF
Shares in issue:
11.98 million
Sector:
Biotechnology
Exchange:
SIX Swiss Exchange
Country:
Switzerland
Currency:
Swiss Franc
Indices:
Swiss All Share Index

Key personnel

  • David Veitch
    Chief Executive Officer, Member of the Management Committee
  • Adesh Kaul
    Member of the Management Committee, Chief Financial Officer
  • Gerrit Hauck
    Member of the Management Committee, Chief Technology Officer
  • Laurenz Kellenberger
    Member of the Management Committee, Chief Scientific Officer
  • Damian Heller
    General Counsel, Corporate Secretary
  • Peter Bielmeier
    Head of Global Quality Management
  • Ursula Eberhardt
    Head of Global Human Resources
  • Marc Engelhardt
    Member of the Management Committee, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.